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Background:We retrospectively investigated our hypothesis that pre-percutaneous coronary intervention (PCI)
procedural therapeutic hypothermia may have clinical advantages in patients with a profound cardiogenic
shock complicating anterior ST-segment elevation myocardial infarction (STEMI).
Methods: Of 483 consecutive patients treated with PCI for a ﬁrst anterior STEMI including 31 patients with
aborted sudden cardiac arrest between 2009 and 2013, a total of 37 consecutive patients with an anterior
STEMI complicated with profound cardiogenic shock deﬁned as the presence of hyperlactic acidemia (serum
levels of lactate N4 mmol/L) with mechanical circulatory support were identiﬁed. An impaired myocardial
tissue-level reperfusion (angiographic myocardial blush grade 0 or 1) and in-hospital mortality were evaluated
in accordance with the presence or absence of pre-PCI procedural therapeutic hypothermia.
Results: Thirteen patients were treated with pre-PCI procedural therapeutic hypothermia and 24 were not
inducted with therapeutic hypothermia. Five patients with and 18 without pre-PCI procedural therapeutic
hypothermia impaired myocardial tissue-level reperfusion (38% vs. 75%, p = 0.037). A total of 26 patients
with in-hospital death (overall in-hospital mortality 70%) were composed of 6 with and 20 without therapeutic
hypothermia (in-hospital mortality 46% vs. 83%, p = 0.028). A multivariate analysis demonstrated a signiﬁcant
association of pre-PCI procedural therapeutic hypothermia (p=0.021)with in-hospital survival beneﬁt. Adverse
events associated with therapeutic hypothermia were not found in 12 patients who completed this treatment.
Conclusions: The present study may imply a crucial possibility of clinical beneﬁts of pre-PCI procedural
therapeutic hypothermia in patients with a cardiogenic shock complicating anterior STEMI.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A complication of cardiogenic shock remains a leading cause of
death not showing any improvements in in-hospital mortality in
patients with a ST-segment elevation myocardial infarction (STEMI)
despite early prompt percutaneous coronary intervention (PCI) with
mechanical circulatory support [1–5]. The fatal clinical features of a car-
diogenic shock complicating STEMI are mainly composed of systemic
microcirculatory and cellular distress resulting in a development of
multi-organ dysfunction syndromes [6]. Recently we demonstrated a
possible role of exaggerated inﬂammation in the pathogenesis oflar Medicine, Sakakibara Heart
l.: +81 42 314 3111; fax: +81
land Ltd. This is an open access articlexcessive systemic as well as myocardial tissue-level mal-perfusion in
those treated with PCI for a cardiogenic shock complicating STEMI [7].
Therapeutic hypothermia is widely available and has become an
established standard of care for patients with post-cardiac arrest
syndromes [8]. Feasibility of using therapeutic hypothermia in combina-
tion with emergency PCI in patients with STEMI with post-cardiac arrest
syndromes had also been recognized [9–11]. One of the main features
to provide clinical beneﬁts of therapeutic hypothermia has beenproposed
to limit a systemic ischemia–reperfusion injury mediated through atten-
uating widespread systemic inﬂammatory response in those with post-
cardiac arrest syndromes [12,13]. If so, the clinical advantages of thera-
peutic hypothermia may exist in those with a cardiogenic shock compli-
cating STEMI who presented exaggerated inﬂammation.
In the present study, to address our hypothesis that therapeutic hy-
pothermia preceding PCImay provide clinical beneﬁts in patientswith a
cardiogenic shock complicating STEMI, we retrospectively analyzede under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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genic shock complicating STEMI.2. Methods
2.1. Study patients (Fig. 1)
From a total of 483 consecutive patients treated with PCI for a ﬁrst
anterior STEMI including 31 patientswith aborted sudden cardiac arrest
between April 2009 and July 2013, 60 patients with cardiogenic shock
including some with aborted sudden cardiac arrest were screened by
the medical staff for inclusion in this study. The eligibility criteria were
as follows; 1) clinical manifestations of profound cardiogenic shock on
hospital admission or sustained more than 30 min after successful re-
suscitation, so called post-resuscitation shock [14], which revealed a
systolic blood pressure of less than 90mmHg or a mean blood pressure
less than 70mmHgdespite high-dose inotrope infusion, clinical signs of
respiratory distress with pulmonary congestion, impaired end-organ
perfusion such as cool extremities, perspiration, prostration and so
necessitates mechanical circulatory support such as intra-aortic balloon
pumping and/or percutaneous cardio-pulmonary bypass with mechan-
ical ventilation [15]. 2) A proof of severe abnormality in tissue oxygen
metabolism deﬁned by a presence of arterial blood levels of lactate
over 4 mmol/L (i.e. severe metabolic acidemia) on hospital admission
or 30 min after resuscitation [16–18]. 3) Therapeutic hypothermia
preceded PCI, if applied. According to these eligibility criteria, 23 pa-
tients were excluded because 4 were dead before PCI, 4 had unneces-
sary mechanical circulatory support, 10 had less severe metabolic
acidemia, and 5 had post-PCI procedural therapeutic hypothermia. Fi-
nally 37 patients (28 men, 70 ± 13 years) with severe metabolic
acidemia and that underwent PCI with mechanical circulatory supportFig. 1. Flowchart of selection of study population. STEMI denotes ST-segment elevation
myocardial infarction, PCI, percutaneous coronary intervention.for a cardiogenic shock complicating ﬁrst anterior STEMIwere recruited
in this study. Of those, 13 patients were treatedwith pre-PCI procedural
therapeutic hypothermia and 24 were not inducted with therapeutic
hypothermia. Our study patientswere coincidedwith the recent recom-
mendation of the cardioprotection study in STEMI such as anterior
STEMI and pre-PCI procedural therapeutic intervention [19]. All patients
or an immediate family member providedwritten, informed consent to
attend our clinical investigation at the time of hospital admission. The
study protocol was approved by our institutional review board.
2.2. Therapeutic hypothermia
Of the 13 patients treated with therapeutic hypothermia, 11 were
resuscitated from ventricular ﬁbrillation and/or pulseless ventricular
tachycardia, and 2 were initiated with therapeutic hypothermia to pro-
tect brain damages from mal-perfusion due to a critical shock state at
the discretion of the physician in charge. Of those with therapeutic
hypothermia, 9 patients underwent endovascular cooling using a heat
exchanger with the Capiox® percutaneous cardio-pulmonary bypass
system (Termo Inc., Tokyo, Japan) and 4 underwent surface cooling
using the Arctic Sun® temperature management system (Medivance
Corp, Louisville, CO) in accordance with our protocol for treatment with
therapeutic hypothermia. Brieﬂy, all patients were sedated during the in-
duction and maintained with therapeutic hypothermia with mechanical
ventilation achieving arterial oxyhemoglobin saturation N94% with a
minimum concentration of FiO2 and monitored the core temperature
using a pulmonary artery or urinary catheter with a temperature sensor
in the usual manner. With the rapid infusion of ice-cold, isotonic, non-
glucose-containing ﬂuid (30 mL/kg), patients were rapidly cooled to
34 °C. Aftermaintaining therapeutic hypothermia for 12–24h, rewarming
was started by 0.5 °C every 12 h to 36 °C under feedback from a continu-
ous measurement of core temperature to the cooling devices.
2.3. PCI procedure
PCI with coronary stent deployment was performed with the con-
ventional technique to eliminate occlusion or sub-occlusion of the left
main and/or proximal left anterior descending coronary artery. Dual
anti-platelet drug therapy with aspirin and either clopidogrel or
ticlopidine but not glycoprotein IIb/IIIa inhibitors was initiated in all pa-
tients. Deployment of stent with pre-dilatation or directly and also use
of an aspiration catheter to retrieve culprit coronary thrombus was up
to the physician in charge. Because of refractory hemodynamic instabil-
ity, an intra-aortic balloon counterpulsation and/or percutaneous
cardio-pulmonary bypass were inducted before PCI in all the patients.
The mean time from hospital arrival to PCI was 50 ± 48 min (median
33 min).
Pre- and post-procedural culprit epicardial coronary ﬂowwas evalu-
ated by Thrombolysis inMyocardial Infarction (TIMI) ﬂow grade from 0
to 3, with the highest grade indicating normal coronary reﬂow [20].
Myocardial tissue-level reperfusion was evaluated by angiographic
myocardial blush grade from 0 to 3, with the highest grade indicating
normal myocardial tissue-level reperfusion [21]. Impaired myocardial
tissue-level reperfusion was deﬁned by the presence of post-PCI proce-
dural angiographic myocardial blush grade 0 or 1 under themechanical
and pharmacological circulatory supports.
2.4. Clinical assessments
The degree of myocardial tissue-level reperfusion and in-hospital
mortality were evaluated to address whether there are any clinical ben-
eﬁts in those treated with pre-PCI procedural therapeutic hypothermia
for a profound cardiogenic shock complicating anterior STEMI. The ad-
verse effects of therapeutic hypothermia such as PCI related major
bleeding, refractory infection, and electrolyte abnormality often related
to dysrhythmias were also evaluated [8].
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Continuous variables are presented as mean ± SD. To compare var-
iables between patients with and without therapeutic hypothermia, p
values were obtained by Student's t-test or the Mann–Whitney test
for continuous variables or the chi-square test for categorical variables.
The 30-day in-hospital mortality was evaluated by the Kaplan–Meier
analysis with the Log-rank and the Breslow–Gehan–Wilcoxon tests, in
accordance with the presence or absence of pre-PCI procedural
therapeutic hypothermia. The Cox proportional hazard model was
used to assess an association of myocardial tissue-level reperfusion
with all-cause in-hospital death. Logistic regression analysis was per-
formed to identify variables that were independently associated with
in-hospital survival. Statistical signiﬁcance was set at p values of b0.05.
3. Results
Demographic characteristics of the present study revealed a mean
age of 70 ± 14 years, 65% male, 41% hypertension, and 49% diabetes
mellitus. Time periods from hospital admission to PCI were 44 ±
39 min and mean length of hospital stay was 28 ± 35 days. Patients
with and without therapeutic hypothermia showed no differences in
vital signs and a severity of metabolic acidosis upon hospital admission
(Table 1). Those with therapeutic hypothermia were mostly resuscitat-
ed with induction of therapeutic hypothermia before PCI, and soTable 1
Baseline demographic, clinical and angiographic characteristics of 37 patients undergoing PCI f
hypothermia.
Age, year
Male sex, no (%)
Body mass index, kg/m2
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Heart rate, beats/min
Shock index, beats/min/mm Hg
Creatine kinase-MB on admission, IU/L
Hypertension, no (%)
Dyslipidemia, no (%)
Current smoking, no (%)




Arterial blood bicarbonate, mmol/L
Arterial blood lactate, mmol/L
Base excess, mmol/L
Arterial blood glucose, mg/dL





Resuscitation before PCI, no (%)
Time from symptom onset to hospital admission, min
Time from hospital admission to induction of therapeutic hypothermia, min
Time from hospital admission to target temperature, min
Time from hospital admission to PCI, min
Left main trunk as the infarct-related coronary artery, no (%)
Multi-vessel coronary artery diseases, no (%)
Pre-PCI procedural TIMI ﬂow grade 0, no (%)
Post-PCI procedural TIMI ﬂow grade 3, no (%)
Thrombus aspiration, no (%)
Intra-aortic balloon counterpulsation, no (%)
Percutaneous cardio-pulmonary bypass, no (%)
Plus–minus values are mean ± SD. PCI denotes percutaneous coronary intervention, STEMI ST
oxygen, PaCO2 partial pressure of carbon dioxide and TIMI thrombolysis in myocardial infarctirelatively spent time from hospital admission to PCI. All of the 13 pa-
tients with therapeutic hypothermia had achieved the target core tem-
perature of 34 °C before PCI. The characteristics of coronary angiogram
and PCI procedures were not different between those with and without
therapeutic hypothermia except for the high prevalence of the use of
percutaneous cardio-pulmonary bypass in thosewith therapeutic hypo-
thermia. Despite a similar achievement of post-PCI procedural TIMIﬂow
grade III, an incidence of angiographic myocardial blush grade 0 and/or
1 was signiﬁcantly different between thosewith andwithout therapeu-
tic hypothermia (Fig. 2A). A total of 26 patients were in-hospital dead,
thereby overall in-hospital mortality was 70%. In detail, one patient
with therapeutic hypothermia and 8 without hypothermia were dead
within 24 h after hospital admission (8% vs. 33%, p = 0.063), and 6
patients with and 20 without therapeutic hypothermia were ﬁnally
in-hospital dead (46% vs. 83%, p = 0.028). As shown in Fig. 2B, the 30-
day in-hospital survival curve was signiﬁcantly different in accordance
with the presence or absence of pre-PCI procedural therapeutic
hypothermia. In the Cox proportional hazardmodel, post-PCI procedur-
al angiographic myocardial blush grade 0 or 1 was highly associated
with in-hospital death (hazard ratio, 5.614; 95% conﬁdence interval,
2.095–19.491, p = 0.003). The logistic multivariate analysis demon-
strated pre-PCI procedural therapeutic hypothermia as a potent
contributor to in-hospital survival beneﬁts (Table 2). There were no ad-
verse events related with therapeutic hypothermia in 12 patients who
completed this treatment (Table 3).or a profound cardiogenic shock complicated anterior STEMI with or without therapeutic





65 ± 12 69 ± 13 0.098
11 (85) 13 (54) 0.133
24 ± 4 22 ± 3 0.110
88 ± 32 92 ± 18 0.679
47 ± 18 49 ± 13 0.768
95 ± 31 94 ± 28 0.969
1.22 ± 0.82 1.06 ± 0.39 0.540
67 ± 153 60 ± 68 0.894
6 (46) 9 (38) 0.865
3 (23) 3 (13) 0.705
7 (54) 6 (25) 0.160
3 (23) 15 (63) 0.051
7.16 ± 0.19 7.24 ± 0.16 0.188
198 ± 154 128 ± 92 0.154
48 ± 23 38 ± 15 0.202
16.9 ± 3.1 16.5 ± 4.4 0.693
8.76 ± 4.33 7.17 ± 3.58 0.280
−11.7 ± 3.6 −11.4 ± 5.6 0.813
291 ± 48 293 ± 116 0.946
13.1 ± 5.7 13.3 ± 4.4 0.896
12.6 ± 2.4 12.3 ± 2.4 0.678
1.53 ± 1.35 1.53 ± 0.85 0.998
138 ± 3 136 ± 5 0.394
4.1 ± 0.8 4.3 ± 0.6 0.447
11 (85) 12 (50) 0.025
22 ± 23 81 ± 77 0.002
19 ± 8 – –
83 ± 66 – –
85 ± 67 46 ± 21 0.060
6 (46) 6 (25) 0.189
8 (62) 17 (71) 0.716
7 (54) 20 (83) 0.121
9 (69) 15 (63) 0.953
8 (62) 12 (50) 0.737
13 (100) 24 (100) 0.999b
9 (69) 6 (25) 0.022
-segment elevation myocardial infarction, pH potential hydrogen, PaO2 partial pressure of
on.
Fig. 2. A. Distribution of post-PCI procedural myocardial blush grade. IQR denotes interquartile range, C.I., conﬁdence interval. B. The 30-day in-hospital mortality in the study population.
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In the present study, we found 1) a crucial difference in the preva-
lence of impaired myocardial tissue-level reperfusion and in-hospital
mortality in accordance with the presence or absence of pre-PCI proce-
dural therapeutic hypothermia in patients with a profound cardiogenic
shock complicating anterior STEMI. 2) A pivotal association between
impaired myocardial tissue-level reperfusion and in-hospital mortality
in those with profound cardiogenic shock. 3) Therapeutic hypothermia
did not cause any serious disadvantages in those who completed this
treatment in the setting of a profound cardiogenic shock complicating
STEMI. Thus, the present ﬁndings may provide a great possibility that
pre-PCI procedural therapeutic hypothermia would ameliorate in-
hospital clinical features in patients with a profound cardiogenic shock
complicating anterior STEMI.
As shown in previous studies, in-hospital death ismainly caused by a
high incidence of severe multi-organ dysfunction syndromes within a
couple of days after the onset of cardiogenic shock in those with
STEMI [5,6]. Importantly, fatal clinical outcomes in a cardiogenic shock
complicating STEMI were associated with the widespread systemic in-
ﬂammatory response syndrome showing high serum levels of
interleukin-6 [22,23], high scores of either Acute Physiology and Chron-
ic Health Evaluation II [24] or Simpliﬁed Acute Physiology Score II [25],
but no less associatedwith cardiac dysfunction itself [5]. Metabolic crisis
showing high serum levels of lactate or high base deﬁcit was also recog-
nized as one of the strongest predictors of fatal outcomes in patients
with a cardiogenic shock complicating STEMI [5,26]. In view of the
rapid development of severe multi-organ dysfunction syndromes with
systemic inﬂammatory response syndrome in those with a cardiogenic
shock complicating STEMI, we postulate to restore systemic homeosta-
sis via the regulation of exaggerated systemic inﬂammation as one of
the goals of treatment in those with critical cardiogenic shock [6,27].
Therapeutic hypothermia is widely available and has become an
established standard of care for patients with post-cardiac arrest syn-
dromes [28]. Non-randomized trials have also reported the feasibility
of combination of therapeutic hypothermia with PCI in the setting ofTable 2
Logistic regression analysis with in-hospital survival as the dependent variable.
Variable Standard error
Time from symptom onset to hospital admission 0.007
Percutaneous cardio-pulmonary bypass 0.602
Pre-PCI therapeutic hypothermia 0.642
PCI denotes percutaneous coronary intervention.STEMI [11]. The clinical beneﬁts of therapeutic hypothermia in the pre-
vention of a systemic ischemia–reperfusion injury as well as systemic
inﬂammatory response in those with post-cardiac arrest syndromes
have been proposed by several potential mechanisms such as
enhancing cellular membrane integrity through preserved adenosine
triphosphate with a reduction in metabolic demand and glucose con-
sumption [29], prevention of mitochondrial damages via the inhibition
of calcium-induced mitochondrial permeability transition pore [30],
and an improvement inmicrocirculation [31]. Furthermore, a reduction
in reactive oxygen species [32] and suppression of pro-inﬂammatory
mediators [13] during therapeutic hypothermia may be of great beneﬁt
to ameliorate systemic and also myocardial tissue-level ischemia–
reperfusion injury [12]. Recently a clinical feasibility and also advan-
tages of pre-PCI procedural therapeutic hypothermia in those with
STEMI had been reported [33]. A couple of studies also reported feasibil-
ity in therapeutic hypothermia in patients with STEMI complicated
with cardiogenic shock [34–36]. In the present study, we found a crucial
possibility of pre-PCI procedural therapeutic hypothermia for a decrease
in an incidence of impaired myocardial tissue-level reperfusion and an
improvement in in-hospital survival rate in those with a profound cardio-
genic shock complicated anterior STEMI. Thus, we believe that a systemic
therapeutic hypothermia prior to coronary reperfusion must be the
promising challenges to overcome systemic microcirculatory and cellular
distress syndrome in this critical disorder. Future investigations warrant a
validation of pre-PCI procedural therapeutic hypothermia as a potential
strategy in patientswith a profound cardiogenic shock complicating STEMI.
5. Study limitations
We have several limitations to putting an accurate interpretation of
our ﬁndings in the present study. First, this was a retrospective study
with a small number of study subjects. There was a demographic bias
in the study patients because those treated with therapeutic hypother-
mia were mostly resuscitated before PCI. So, our ﬁndings did not have
power to conclude the clinical beneﬁts of pre-PCI procedural therapeu-





Clinical data before and during therapeutic hypothermia in 12 patients with a profound
cardiogenic shock complicated anterior STEMI.
Pre-PCI procedural
therapeutic hypothermia
Baseline 24 h later p value
Systolic blood pressure, mm Hg 107 ± 24 115 ± 16 0.423
Diastolic blood pressure, mm Hg 60 ± 17 61 ± 8 0.915
Heart rate, beats/min 88 ± 28 84 ± 16 0.766
Arterial blood pH 7.09 ± 0.17 7.42 ± 0.12 0.001
PaO2, mm Hg 193 ± 137 158 ± 73 0.503
PaCO2, mm Hg 55 ± 22 41 ± 12 0.103
Arterial blood bicarbonate, mmol/L 17.7 ± 2.4 24.4 ± 1.4 0.001
Arterial blood lactate, mmol/L 9.12 ± 3.40 2.96 ± 1.50 0.001
Base excess, mmol/L −12.0 ± 4.1 0.28 ± 2.42 0.001
White blood cell counts, x103/μL 13.6 ± 6.3 14.1 ± 6.1 0.858
Serum creatinine, mg/dL 1.61 ± 1.39 1.49 ± 1.52 0.849
Serum sodium, mmol/L 137 ± 4 138 ± 3 0.757
Serum potassium, mmol/L 4.1 ± 0.9 3.9 ± 0.7 0.539
Plus–minus values are mean ± SD. PCI denotes percutaneous coronary intervention,
STEMI ST-segment elevation myocardial infarction, pH potential hydrogen, PaO2 partial
pressure of oxygen and PaCO2 partial pressure of carbon dioxide.
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ﬁnd any disadvantage such as serious arrhythmia, infection, bleeding,
etc. during therapeutic hypothermia in the setting of profound cardio-
genic shock, the optimal temperature and duration for therapeutic hy-
pothermia in those with a profound cardiogenic shock complicating
STEMI are still unknown [37]. Third, because cardiogenic shock has a
wide clinical spectrum from mild to profound, there is also a caution
to translate the present study into a whole range of those with cardio-
genic shock.
6. Conclusions
The present study may provide a pivotal insight into the possibility
of clinical beneﬁts of pre-PCI procedural therapeutic hypothermia in pa-
tients with a profound cardiogenic shock complicating anterior STEMI.
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